4-Fluoro-DMT
4-Fluoro-DMT, also known as 4-fluoro-N,''N''-dimethyltryptamine, is a serotonin receptor agonist of the tryptamine family and a close analogue of psilocin and dimethyltryptamine. It is a modestly selective serotonin 5-HT2C receptor full agonist and doesn't appear to produce psychedelic-like effects in animals but instead produces antiobsessional-like effects. It has been encountered online as a novel designer drug, with claimed mild entactogen-like effects.
Use and effects
According to an unverified online anecdotal report, 4-fluoro-DMT is said to produce mild entactogen-like effects, such as enhanced sociability, empathy, and communication and a feeling of peace, with few or no psychedelic effects. It was described as being like a lighter version of MDMA and being like an LSD or psilocybin afterglow. However, there was also said to be a slight feeling of "psychedelic dissociation". The drug is said to be active at doses of 10 to 30mg sublingually and 15mg by inhalation. Its onset is said to be 40minutes and its duration is said to be 2 to 3hours.Interactions
Pharmacology
Pharmacodynamics
4-Fluoro-DMT's affinity for the serotonin 5-HT1A receptor was 135nM. This can be compared to psilocin's affinity of 378nM and serotonin's affinity of 1.7nM. In another study, 4-F-DMT showed affinities of 335nM for the serotonin 5-HT2A receptor, 8.39nM for the serotonin 5-HT2B receptor, and 82–84nM for the serotonin 5-HT2C receptor. Its activational potencies and efficacies were 949nM at the serotonin 5-HT2A receptor, 1,180nM at the serotonin 5-HT2B receptor, and 99nM at the serotonin 5-HT2C receptor. 4-F-DMT showed dramatically less potent values at the serotonin 5-HT2A and 5-HT2B receptors compared to psilocin, whereas its potency was less markedly reduced at the serotonin 5-HT2C receptor. Hence, whereas psilocin is a balanced agonist of the serotonin 5-HT2 receptors, 4-F-DMT is a selective serotonin 5-HT2C receptor agonist with about 10-fold preference for activation of this receptor over the serotonin 5-HT2A and 5-HT2B receptors. Moreover, whereas psilocin was a partial agonist of the serotonin 5-HT2C receptor, 4-F-DMT had higher efficacy and was a full agonist.4-F-DMT produced partial generalization to LSD in animal drug discrimination tests, but this was not statistically significant and an was not calculated. It also failed to substitute for DOI in drug discrimination tests. Conversely, psilocin produced full generalization at much lower doses. Hence, 4-F-DMT may not be hallucinogenic in humans. On the other hand, the drug was dose-dependently and strongly active in producing antiobsessional-like effects in an animal model of obsessive–compulsive disorder , an effect that it is thought may be mediated by serotonin 5-HT2C receptor agonism.